[Form 4] Connect Biopharma Holdings Ltd Insider Trading Activity

LIU JEAN I reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

LIU JEAN I reported acquisition or exercise transactions in this Form 4 filing.

Connect Biopharma Holdings Ltd director Jean I. Liu received a stock grant of 5,061 ordinary shares as board compensation. The shares are fully vested and were taken in lieu of cash for her 2026 annual board retainers, covering service during the first quarter of 2026.

The number of shares was calculated by dividing the applicable equity value by the average closing price of the company’s ordinary shares over the 30 consecutive trading days immediately before March 31, 2026, then rounded down to the nearest whole share. This is a routine, compensation-related equity award rather than an open‑market purchase or sale.

Insider Trade Summary

Grant/Award: 5,061 shares

Grant/Award 1 txn

Insider LIU JEAN I

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares	5,061	$0.00	$0.00

Holdings After Transaction: Ordinary Shares — 5,061 shares (Direct)

Footnotes (1)

1. F1. In accordance with the Connect Biopharma Holdings Limited Non-Employee Director Compensation Program, Ms. Liu elected to receive fully vested shares in lieu of cash compensation for her 2026 annual board retainers. Accordingly, the fully vested ordinary shares were granted to Ms. Liu for her service as a director during the first quarter of 2026. The number of shares received in lieu of cash was calculated by dividing the applicable value of the equity by the average closing price of our ordinary shares over the 30 consecutive trading days immediately preceding March 31, 2026, rounded down to the nearest whole share.

Key Figures

Shares granted: 5,061 shares Price per share: $0.0000 per share Post-transaction holdings: 5,061 shares +2 more

5 metrics

Shares granted 5,061 shares Ordinary shares granted as 2026 first-quarter board retainers

Price per share $0.0000 per share Reported transaction price for compensation grant

Post-transaction holdings 5,061 shares Total ordinary shares held directly after the grant

Transaction code A Grant, award, or other acquisition of non-derivative securities

Transaction direction acquire Equity award received as compensation, not market purchase

Key Terms

Non-Employee Director Compensation Program, in lieu of cash compensation, fully vested ordinary shares, average closing price

4 terms

Non-Employee Director Compensation Program financial

"In accordance with the Connect Biopharma Holdings Limited Non-Employee Director Compensation Program, Ms. Liu elected to receive fully vested shares..."

in lieu of cash compensation financial

"Ms. Liu elected to receive fully vested shares in lieu of cash compensation for her 2026 annual board retainers."

fully vested ordinary shares financial

"Accordingly, the fully vested ordinary shares were granted to Ms. Liu for her service as a director..."

average closing price financial

"calculated by dividing the applicable value of the equity by the average closing price of our ordinary shares over the 30 consecutive trading days..."

The average closing price is the arithmetic mean of a security’s end-of-day prices over a chosen period, found by adding each day’s closing price and dividing by the number of days. It smooths out daily ups and downs to show a typical market value—like averaging daily temperatures to understand a month’s climate—and helps investors spot trends, judge whether a stock is generally rising or falling, and make clearer buy or sell decisions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/02/2026 - 04:25 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LIU JEAN I

(Last) (First) (Middle)

3580 CARMEL MOUNTAIN ROAD, SUITE 200

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Connect Biopharma Holdings Ltd [ CNTB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	03/31/2026		A		5,061(1)	A	$0	5,061	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. In accordance with the Connect Biopharma Holdings Limited Non-Employee Director Compensation Program, Ms. Liu elected to receive fully vested shares in lieu of cash compensation for her 2026 annual board retainers. Accordingly, the fully vested ordinary shares were granted to Ms. Liu for her service as a director during the first quarter of 2026. The number of shares received in lieu of cash was calculated by dividing the applicable value of the equity by the average closing price of our ordinary shares over the 30 consecutive trading days immediately preceding March 31, 2026, rounded down to the nearest whole share.

Remarks:

	/s/ Lisa Peraza attorney-in-fact for Jean I Liu	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)